Paper Review Records
All Paper Review Records
11 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
80
days
Inhibiting or harnessing fratricide in CAR-engineered cell therapy: challenges and opportunities
Authors
Andrew N. Gorobchenko; Karina T. Umbetova; Abdigaffor Gadaev; Nargiza Mahkamova; Nasiba Sabirova; Aziz KubaevShow moreShow less
Affiliations
1. Department of Infectious Diseases, Institute of Public Health named after F.F. Erisman I.M,. Sechenov First Moscow State Medical University of the Russian Federation (Sechenov University), Moscow, Russia; 2. Department of Internal Medicine in Family Medicine, Tashkent State Medical University, Tashkent, Uzbekistan; 3. Republican Specialized Scientific and Practical Medical Center of Cardiology, Tashkent, Uzbekistan; 4. Bukhara State Pedagogical Institute, Bukhara, Uzbekistan; 5. Department of Maxillofacial Surgery, Samarkand State Medical University, Samarkand, UzbekistanShow moreShow less
124
days
Pharmacokinetic comparison of cisplatin administration via HIPEC and intravenous infusion in a porcine model
Authors
Christina Harlev; Elisabeth Krogsgaard Petersen; Mats Bue; Lone Kjeld Petersen; Johanne Gade Lilleøre; Anne Vibeke Schmedes; Bo Martin Bibby; Maiken StillingShow moreShow less
Affiliations
1. Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; 2. Aarhus Denmark Microdialysis Research (ADMIRE), Orthopaedic Research Laboratory, Aarhus University Hospital, Aarhus, Denmark; 3. Department of Orthopaedic Surgery, Aarhus University Hospital, Aarhus, Denmark; 4. Department of Gynecology and Obstetrics, Odense University Hospital, Odense, Denmark; 5. Department of Clinical Research, University of Southern Denmark, Odense, Denmark; 6. Department of Biochemistry and Immunology, Lillebaelt Hospital, University Hospital of Southern, Vejle, Denmark; 7. Department of Biostatistics, Aarhus University, Aarhus, DenmarkShow moreShow less
42
days
Benefit of plasma cystatin C for carboplatin individual dosing in a patient with spinal amyotrophy
Authors
Matthieu Gracia; Sabrina Marsili; Julien Vintejoux; Laurence Gladieff; Etienne Chatelut; Fabienne ThomasShow moreShow less
Affiliations
1. Univ Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole, Inserm, CRCT, Toulouse, France; 2. Univ Toulouse, Oncopole Claudius-Regaud, IUCT-Oncopole, Toulouse, FranceShow moreShow less
103
days
Lack of effects of S -equol-containing supplement on the pharmacokinetics of oral hormone therapy drugs for breast cancer
Authors
Takehiko Sambe; Chiyo K. Imamura; Noriko Hida; Taigi Yamazaki; Takuya Mizukami; Kakei Ryu; Koya Fukunaga; Taisei Mushiroda; Haruna Miyakawa; Shigeto Uchiyama; Naoki Uchida; Shinichi KobayashiShow moreShow less
Affiliations
1. Division of Clinical Pharmacology, Department of Pharmacology, Showa Medical University School of Medicine, Tokyo, Japan; 2. Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan; 3. Advanced Cancer Translational Research Institute, Showa Medical University, Tokyo, Japan; 4. Division of Clinical Research and Development, Department of Clinical Pharmacy, Showa Medical University School of Pharmacy, Tokyo, Japan; 5. RIKEN Center for Integrative Medical Sciences, Yokohama, Japan; 6. Nutraceuticals Research Institute, Otsuka Pharmaceutical Co., Ltd., Saga, JapanShow moreShow less
120
days
Presence of drug-drug interactions between esomeprazole and an ALK tyrosine kinase inhibitor (Dirozalkib)
Authors
Lin Fang; Xin Jiang; Kexiu Song; Ping Shi; Li Wang; Lingmei Xu; Xianghui Duan; Fei Liu; Feifei Sun; Rongxin Ban; Yaping Ma; Chenjing Wang; Yu CaoShow moreShow less
Affiliations
1. Phase I Clinical Research Center, The Affiliated Hospital of Qingdao University, Qingdao, China; 2. Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, China; 3. Clinical Medicine Department, XuanZhu Biopharm Co., Ltd, Shijiazhuang, China; 4. Clinical Pharmacology Department, XuanZhu Biopharm Co., Ltd, Shijiazhuang, China; 5. Biostatistics Department, XuanZhu Biopharm Co., Ltd, Shijiazhuang, ChinaShow moreShow less
48
days
Association of DPYD rs4294451, plasma uracil concentration, and sex with 5-fluorouracil exposure in patients with gastrointestinal cancer
Authors
Gabriel A. Brooks; Dylan B. Ness; Kathryn C. Hourdequin; Gregory H. Ripple; Manik Amin; Sierra Lord-Halvorson; Wahab A. Khan; Sophie J. Deharvengt; Vincent Busque; Konstantin H. Dragnev; Wenyan Zhao; Tor D. Tosteson; Lionel D. LewisShow moreShow less
Affiliations
1. Dartmouth Cancer Center, Lebanon, USA; 2. Geisel School of Medicine, Lebanon, USA; 3. Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, USA; 4. University of Chicago Comprehensive Cancer Center, Chicago, USAShow moreShow less
FAQ
How long does CANCER CHEMOTHERAPY AND PHARMACOLOGY take to review a manuscript?
As of 2026-11-19, CrushSCI has 11 complete review records for CANCER CHEMOTHERAPY AND PHARMACOLOGY. The fastest paper went from submission to acceptance in 42 days (Benefit of plasma cystatin C for carboplatin individual dosing in a patient with spinal amyotrophy, received 2025-09-22, accepted 2025-11-03); the slowest took 152 days. The average is 99.8 days and the median is 103 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
